التفاصيل البيبلوغرافية
| العنوان: |
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. |
| المؤلفون: |
Fountzilas, Elena, Lampaki, Sofia, Koliou, Georgia-Angeliki, Koumarianou, Anna, Levva, Sofia, Vagionas, Anastasios, Christopoulou, Athina, Laloysis, Athanasios, Psyrri, Amanda, Binas, Ioannis, Mountzios, Giannis, Kentepozidis, Nikolaos, Kotsakis, Athanassios, Saloustros, Emmanouil, Boutis, Anastasios, Nikolaidi, Adamantia, Fountzilas, George, Georgoulias, Vassilis, Chrysanthidis, Miltiadis, Kotteas, Elias |
| المصدر: |
Cancer Immunology, Immunotherapy; Feb2022, Vol. 71 Issue 2, p327-337, 11p |
| مصطلحات موضوعية: |
CANCER patients, AUTOIMMUNE diseases, DRUG side effects, NON-small-cell lung carcinoma, IMMUNE checkpoint inhibitors |
| مستخلص: |
Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records of patients with cancer and underlying AID who received ICI. The primary endpoint was progression-free survival (PFS). Results: Among 123 patients with pre-existing AID who received ICI, the majority had been diagnosed with non-small cell lung cancer (NSCLC, 68.3%) and melanoma (14.6%). Most patients had a rheumatologic (43.9%), or an endocrine disorder (21.1%). Overall, 74 (60.2%) patients experienced an immune-related adverse event (irAE) after ICI initiation, AID flare (25.2%), or new irAE (35%). Frequent irAEs included thyroiditis, dermatitis and colitis. ICI was permanently discontinued due to unacceptable (8.1%) or fatal (0.8%) toxicity. In patients with NSCLC, corticosteroid treatment at the initiation of immunotherapy was associated with poor PFS (HR = 2.78, 95% CI 1.40–5.50, p = 0.003). The occurrence of irAE was associated with increased PFS (HR = 0.48, 95% CI 0.25–0.92, p = 0.026). Both parameters maintained their independent prognostic significance. Conclusions: ICI in patients with cancer and pre-existing AID is associated with manageable toxicity that infrequently requires treatment discontinuation. However, since severe AID flare might occur, expected ICI efficacy and toxicity must be balanced. Clinical trial identifier: NCT04805099 [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Immunology, Immunotherapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder